Studies in Amyotrophic Lateral Sclerosis (ALS) and Other Neurodegenerative Motor Neuron Disorders

Amyotrophic Lateral Sclerosis Clinical Trial

Official title:

Clinical & Genetic Studies in ALS and Other Neurodegenerative Motor Neuron Disorders

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05474235
• Other study ID #: 07-005711
• Secondary ID: 5P01NS084974
• Status: Recruiting
• Start date: December 2007
• Est. completion date: December 2038

Study information

• Verified date: August 2023
• Source: Mayo Clinic
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The purpose of this study is to collect, from patients with sporadic and familial ALS and their family members, clinical data and blood samples for extraction of DNA, RNA, preparation of lymphocytes, plasma and serum to establish a repository for future investigations of genetic contributions to ALS pathogenesis. Blood samples for DNA extraction also would be collected from control subjects with no personal or family history of ALS phenotypes.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 3000
• Est. completion date: December 2038
• Est. primary completion date: December 2038
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria

ALS or Suspected ALS Patient

• Clinical diagnosis of possible, laboratory-supported probable, probable or definite ALS according to modified EL Escorial criteria, suspected ALS according to original El Escorial criteria, or diagnosis of a neurodegenerative disorder with evidence of ALS plus extramotor features; OR

• Blood relative (first, second or third degree) with history of ALS or neurodegenerative disorder with evidence of ALS plus extramotor features; OR:

• A clinical suspicion or referral for ALS;

• > 18 years of age;

• Willing and able to give signed informed consent or assent that has been approved by the Institutional Review Board (IRB).

Blood Relative of ALS Patient

• Family history (first, second or third degree blood relative) of ALS or other motor neuron disease;

• > 18 years of age;

• Willing and able to give signed informed consent that has been approved by the Institutional Review Board (IRB).

Healthy Control

• No personal or family history (first, second or third degree blood relative) of ALS or other motor neuron disease;

• > 18 years of age;

• No personal history of other neurodegenerative disease (i.e., Alzheimer disease, Parkinson disease);

• Willing and able to give signed informed consent that has been approved by the Institutional Review Board (IRB).

Exclusion Criteria:

ALS or Suspected Patient • Limited mental capacity rendering the subject unable to provide written informed consent or assent or comply with standard phlebotomy procedures.

Blood Relative of ALS Patient

• Limited mental capacity rendering the subject unable to provide written informed consent or comply with standard phlebotomy procedures.

Healthy Control Subject

• Personal or family history of dementia or other neurodegenerative disease (Parkinson disease, Alzheimer disease, etc.);

• MoCA score < 26;

• Limited mental capacity rendering the subject unable to provide written informed consent or comply with standard phlebotomy procedures.

Related Conditions & MeSH terms

• Amyotrophic Lateral Sclerosis
• Motor Neuron Disease
• Sclerosis

Locations

Country	Name	City	State
United States	Mayo Clinic Florida	Jacksonville	Florida

Sponsors (2)

Lead Sponsor	Collaborator
Mayo Clinic	National Institute of Neurological Disorders and Stroke (NINDS)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Blood Collection	Total number of blood samples collected	50 years

External Links

•   Mayo Clinic Clinical Trials